Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Bisphosphonates Impair Alveolar Bone Healing After Dental Surgery

By HospiMedica International staff writers
Posted on 09 Jun 2009
A new study has found that bisphosphonates can impair healing and slow turnover of alveolar bone even years after the drugs themselves have been discontinued.

Researchers at the University of Colorado Health Sciences Center (Boulder, USA) and in private practice in Houston (TX, USA) described a 73-year-old woman with a three-year history of metastatic breast adenocarcinoma, who had been taking zoledronic acid chronically as treatment. More...
The patient demonstrated numerous residual "ghost” sockets following tooth extractions, which presented lamina dura outlines visible radiographically, signifying chronic ischemia of the jawbone marrow. The patient had almost no ability to heal or remodel the numerous dental extraction sites, even two years after cessation of the bisphosphonate therapy. Moreover, the patient had no secondary risk factors that could explain the development of these residual sockets, which additionally did not heal despite several courses of debridement and treatment with antibiotics. The authors recommend taking heed when encountering such residual sockets, since their presence of could alert the surgeon to potential healing problems in subsequent surgery or trauma of alveolar bone. The study was published in the March/April 2009 issue of General Dentistry.

"Among patients using bisphosphonates, residual sockets provide additional evidence of poor bone healing or very slow bone turnover,” concluded study authors Kishore Shetty, D.D.S., and oral and maxillofacial pathologist Jerry Bouquot, D.D.S., of the department of medicine and surgical dentistry. "It is critical that dentists and oncologists are aware that this significant complication may occur spontaneously or after any dentoalveolar procedure among the population at risk.”

Bisphosphonates are used to slow osteoclastic and osteoblastic activity in patients with bone metastasis, multiple myeloma, osteitis deformans (Paget's disease), osteoporosis, and breast cancer. Hundreds of cases of bisphosphonate-related osteonecrosis of the jaw have been reported, with the mandible twice as frequently affected as the maxilla, and most cases occurring following high-dose intravenous administration used for some cancer patients. Some 60% of cases are preceded by a dental surgical procedure, and it has been suggested that bisphosphonate treatment should be postponed until the dental work has been completed to eliminate potential sites of infection.

Related Links:

University of Colorado Health Sciences Center




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.